Compare Merck & Co., Inc. (MRK) vs Zoom Video Communications, Inc. (ZM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Zoom Video Communications, Inc. — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Zoom Video Communications, Inc. trades at $96.82 (market cap $28.14B). The key difference: Merck & Co., Inc. is far larger — about 13× Zoom Video Communications, Inc.'s market cap, and Merck & Co., Inc. pays a 2.29% dividend while Zoom Video Communications, Inc. pays none. Which is the better fit depends on your goals.
| MRK | ZM | |
|---|---|---|
Market Cap | $366.28B | $28.14B |
Sector | Health | Technology |
52-Week High | $156.43 | $111.88 |
52-Week Low | $77.60 | $72.72 |
Enterprise Value | $413.04B | $20.95B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Zoom (ZM) trades at $96.44, down 4.83% on the day, amid a bearish technical signal and soft Q3 profit guidance that overshadowed a Q2 earnings beat. The stock shows strong fundamentals with a P/E of 8.95, net income margin of 65.19%, and positive cash flow trends, but faces near-term pressure from investor concerns over growth outlook. Recent board appointments and enterprise revenue strength provide some optimism.
The outlook is mixed; solid profitability and low valuation offer upside potential toward the $119.63 consensus price target, but risks include competitive pressures and execution on guidance. Analyst sentiment is cautious with 55.1% hold ratings, reflecting uncertainty around future growth catalysts versus current operational resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Zoom Video Communications, Inc.
Zoom Video Communications, Inc. develops a people-centric cloud service that transforms real-time collaboration experience. The Company offers unified meeting experience, a cloud service that provides a 3-in-1 meeting platform with HD video conferencing, mobility, and web meetings. Zoom Video Communications serves customers worldwide.
Read more on ZM →
